Liver injury indicators and subsequent cancer development among <scp>non‐fatty</scp> liver population

Ito, Hiroshi; Kimura, Takeshi; Shimbo, Takuro; Higashitani, Michiaki; Yamamoto, Kazuki; Kobayashi, Daiki

doi:10.1002/cam4.5910

Cited by 4 publications

(1 citation statement)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transcatheter arterial chemoembolization was included into the nonsurgical group. 40,41 Furthermore, given prior research that reported the predictive utility of the FIB-4 score for non-HCC cancers, [42][43][44] we also conducted further investigations to assess the ability of the FIB-4 in predicting breast cancer and colorectal cancer.…”

Section: Identification Of Hcc and Non-hcc Cancer Casesmentioning

confidence: 99%

Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study

Shin,

Sohn,

Chang

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

AimHepatocellular carcinoma (HCC) is a major cause of cancer‐related death, with low survival rates worldwide. Fatty liver disease (FLD) significantly contributes to HCC. We studied the screening performance of different methods for identifying HCC in patients with FLD or with metabolic risk factors for FLD.MethodsKorean adults (n=340,825) without a prior HCC diagnosis were categorized into four groups: normal (G1), ≥2 metabolic risk factors (G2), FLD (G3), and viral liver disease or liver cirrhosis (G4). The National Cancer Registry data were used to identify HCC cases within 12 months. We assessed the area under the receiver operating characteristic curve (AUROC), sensitivity, specificity, and positive and negative predictive values of individual or combined screening methods.ResultsIn 93 HCC cases, 71 were identified in G4, while 20 cases (21.5%) in G2 and G3 combined where ultrasound and fibrosis‐4 performed similarly to alpha‐fetoprotein and ultrasound. In G2, fibrosis‐4 and ultrasound had the highest AUROC (0.93 [0.87–0.99]), whereas in G3, the combined screening methods had the highest AUROC (0.98 [0.95–1.00]). The positive predictive value was lower in G2 and G3 than in G4 but was >5% when restricted to a high fibrosis‐4 score.ConclusionsMore than 21% of HCC cases were observed in patients with diagnosed FLD or at risk of FLD with metabolic risk factors. Nevertheless, screening for HCC in individuals without cirrhosis or viral hepatitis yielded very low results, despite the potential value of the fibrosis‐4 score in identifying individuals at high risk of HCC.This article is protected by copyright. All rights reserved.

show abstract

Section: Identification Of Hcc and Non-hcc Cancer Casesmentioning

confidence: 99%

Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study

Shin,

Sohn,

Chang

et al. 2024

Hepatology Research

View full text Add to dashboard Cite

show abstract

Liver injury indicators and subsequent cancer development among non‐fatty liver population

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Fatty liver index as an independent predictor of all-cause and disease-specific mortality

Zhang,

Ren,

et al. 2024

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Purpose: This study aims to assess the prognostic value of the fatty liver index (FLI), a noninvasive tool for hepatic steatosis assessment, in predicting all-cause and disease-specific mortality. Methods: We linked data from the National Health and Nutrition Examination Survey III (1988–1994) with Public-Use Mortality Files, forming a cohort of 11 297 participants with a median follow-up period of 26.25 years. Cox proportional hazards models were used to evaluate the association between FLI and all-cause mortality, while Fine and Gray’s models assessed the relationship between FLI and disease-specific mortality. Results: The FLI ≥ 60 was independently associated with an increased risk of all-cause mortality (hazard ratio = 1.24, P < 0.001), as well as mortality from malignant neoplasms (hazard ratio = 1.18, P = 0.048), diabetes (hazard ratio = 2.62, P = 0.001), and cardiovascular diseases (CVDs) (hazard ratio = 1.18, P = 0.018), compared to FLI < 30. No significant associations were found with Alzheimer’s disease, influenza and pneumonia, chronic lower respiratory diseases, or renal disorders. Subgroup analyses indicated that individuals who were females aged 40–60 (hazard ratio = 1.67, P = 0.003), non-overweight (hazard ratio = 1.75, P = 0.007), or without abdominal obesity (hazard ratio = 1.75, P = 0.007) exhibited a stronger association between FLI ≥ 60 and all-cause mortality. Conclusion: These findings support the prognostic value of the FLI for predicting mortality from all causes, malignant neoplasms, diabetes, and CVDs. Targeted attention is needed in postmenopausal women, non-overweight, and non-abdominally obese populations.

show abstract

Liver injury indicators and subsequent cancer development among non‐fatty liver population

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 4 publications

References 41 publications

Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study

Potential role of Fibrosis‐4 score in hepatocellular carcinoma screening: The Kangbuk Samsung Health Study

Liver injury indicators and subsequent cancer development among non‐fatty liver population

Fatty liver index as an independent predictor of all-cause and disease-specific mortality

Contact Info

Product

Resources

About